Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 36 P65 | DOI: 10.1530/endoabs.36.P65

BSPED2014 Poster Presentations (1) (88 abstracts)

A heterozygous STAT5B variant in a family with short stature and transient hyperprolactinaemia: a possible dominant negative effect

Evelien Pease-Gevers 1 , Julia Kowalczyk 1 , Helen Storr 1 , Lou Metherell 1 & Mehul Dattani 2


1William Harvey Research Institute, Queen Mary University London, London, UK; 2Institute of Child Health, London, UK.


The index case, born to non-consanguineous British parents, was born with a normal birth weight. He grew along the −2.9 S.D. centile from the age of 2 years. Eczema was diagnosed at the age of 2 weeks. Investigations at 3–4 years of age showed: IGF1<25 ng/ml, IGFBP3 1.29 (N 0.8–3.9), prolactin 265–653 mU/l (N 59–271), GH peak (glucagon test) 17.3 ug/l, normal GH peaks on overnight sampling, and an IGF1<25 ng/ml on a standard IGF1generation test. His younger brother had short stature (−2.9 S.D.) with poor height velocity, eczema and mild speech delay, undetectable IGF1, and a GH peak of 13.9 ug/l.

Heights of his mother, maternal aunt and maternal grandmother are ~155 cm (−1.2 S.D.). Mother and maternal aunt were previously investigated for transient hyperprolactinaemia. The mother had low normal IGF1 (113 ng/ml (69–268)) and a detectable random GH (0.3 ug/l).

An extended three step IGF1-generation test (2 weeks GH S.C. at 0.7, 1.4 and 2.4 mg/m2 per day, with wash-out periods) showed little response; index case: step1 IGF1 56 ng/ml, IGFBP3 2.62 mg/l, step 2 IGF1 61 ng/ml, igfbp3 2.87 ng/ml, step 3 IGF1 83 ng/ml (N 57–316), IGFBP3 3.33 (N 1.4–6.1) and brother: step1 and step 2: IGF1<25 ng/ml, step3, IGF1 32 ng/ml, IGFBP3 2.37 mg/l.

Exons and intron–exon boundaries of STAT5B were sequenced. A heterozygous variant c.1433C>T (p.A478V) was found in the index case. The brother and mother but not the father, had the same variant, suggestive of a dominant negative effect or haplo-insufficiency. STAT5B sequencing in maternal aunt and grandmother is underway. The variant occurred in a highly conserved residue and is predicted to alter helix 6, at the end of the DNA-binding domain, and would potentially disrupt function. We hypothesise that this variant has a dominant negative effect on STAT5B function, given the requirement for dimerization of the protein, resulting in moderate short stature with a poor growth rate.

Volume 36

42nd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.